Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Search
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,842.99
(0.45%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)

InhaleRx (ASX: $IRX) pivots to breakthrough cancer pain as primary indication

InhaleRx Ltd (ASX: $IRX) announcement overview


InhaleRx Ltd (ASX: $IRX) has announced its decision to nominate Breakthrough Cancer Pain (BTcP) as the primary area of focus for the proposed Phase 2 clinical trial of IRX211, a cannabinoid derived drug delivered via inhalation. The decision follows a detailed evaluation process and feedback from the US Food & Drug Administration (FDA) in March 2023. The company aims to provide therapeutic solutions in a cost-effective and time-efficient manner, with the overarching goal of achieving a New Drug Approval (NDA) with the FDA.

Executive commentary on the pivot to breakthrough cancer pain


CEO, Mr Darryl Davies said; 'IRX's ability to be nimble has served as a significant advantage in this particular case. Feedback from the FDA from earlier in 2023 resulted in a comprehensive review of potential alternative pain indications. This work has provided us with confidence that BTcP will provide a combination of primary endpoints that are better suited to the characteristics of IRX211 (compared with those of CRPS), resulting in a better-established pathway with a resultant increase in the probability of success.' IRX's Chief Scientific Officer, Dr Rob Jenny, said 'We are excited to apply the learnings made while exploring the orphan disease CRPS as a drug development target to the much larger BTcP patient population.'

Summary of InhaleRx Ltd's pivot and outlook


InhaleRx Ltd (ASX: $IRX) has strategically pivoted to focus on Breakthrough Cancer Pain (BTcP) as the primary indication for the proposed Phase 2 clinical trial of IRX211, citing established indication, FDA vouchers, multiple approvals, larger patient population, and commercial opportunity as key supporting points. The company aims to capture a significant share of the non-opioid cancer pain market with IRX211, which is a cannabinoid derived drug delivered via inhalation. The decision is expected to result in significant time and cost savings across the clinical development timeline. IRX's overarching goal remains to achieve a New Drug Approval (NDA) with the FDA, and it plans to explore opportunities for the application of IRX211 for Complex Regional Pain Syndrome (CRPS) in the future.

Sourcehttps://announcements.asx.com.au/asxpdf/20240110/pdf/05z9x4xsv72n2q.pdf

Share to Social
0 Comments
Inline Feedbacks
View all comments

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions